All News

Updated findings from the MAIA trial support the use of frontline daratumumab plus lenalidomide/dexamethasone in transplant-ineligible NDMM.

In the phase 3 COMPETE trial, ITM-11 met its primary end point of PFS and showed a favorable trend with respect to OS in GEP-NETs.

Patients with breast cancer who received endocrine therapy alone had improved physical health outcomes compared with those who received chemotherapy.

Axillary management of patients with breast cancer such as sentinel lymph node biopsy have evolved substantially over the past 30 years.

Additional results from the phase 3 NIAGARA trial showed improved event-free survival and overall survival with durvalumab/gemcitabine/cisplatin in MIBC.

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.

The FDA has approved 2 denosumab biosimilars for all prior approvals for the reference drugs in patients with cancers and osteoporosis.

The safety profile of trastuzumab deruxtecan in the phase 3 DESTINY-Gastric04 trial was consistent with the established safety profile of the agent.

A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.

The observed safety profile of HA121-28 was similar to that of other multi-targeted RET tyrosine kinase inhibitors.

Julie M. Vose, MD, MBA, discusses some of the lasting effects that the COVID-19 pandemic has had on the current state of cancer care.

AI-powered pathology imaging enables a more comprehensive assessment of tumor microenvironments than humans alone could perceive.

Combining pembrolizumab with pemetrexed met the primary end point of objective response rate in a phase 2 trial.

Retrospective analyses found that antihistamines added to atezolizumab yielded a 46% OS rate, a 48% CSS rate, and a 23% PFS rate in patients with metastatic urothelial carcinoma.

The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.

Data from the RATIONALE-306 trial support the approval of tislelizumab plus chemotherapy in unresectable or metastatic esophageal squamous cell carcinoma.

A real-world study assessed treatment patterns and outcomes of elderly patients with lenalidomide-refractory multiple myeloma after 1 to 3 therapy lines.

Daratumumab would become the sole anti-CD38 agent available for all newly diagnosed multiple myeloma types if approved.

A retrospective cohort study found that, of Medicare decedents with advanced cancer, 45% experienced potentially aggressive end-of-life care.

Data from the DESTINY-Breast06 trial support the positive opinion on trastuzumab deruxtecan as a treatment in HER2-low or HER2-ultralow breast cancer.

Pirtobrutinib demonstrated PFS benefit compared with standard of care in patients with relapsed or refractory CLL in the BRUIN CLL-321 trial.

Antitumor efficacy end points favored placebo over trilaciclib prior to FOLFOXIRI/bevacizumab in patients with untreated metastatic colorectal cancer.

One of the most predictable toxicities of autologous stem cell transplantation for multiple myeloma — even more so than mucositis — is hair loss.

Overall, BMT CTN 0702 showed no improvement in outcomes with added post-ASCT consolidation as compared to standard lenalidomide maintenance.

The absence of a PFS and OS benefit in the transplant arm was consistent across key subgroups in the phase 3 GMMG ReLApsE trial.

In a small cohort of patients with MMS/pMMR CRC, the suvemcitug and envafolimab pharmacokinetic profiles were comparable with prior monotherapy studies.

Pembrolizumab and bevacizumab yielded an ORR of 58.3% vs 12.5% with pembrolizumab monotherapy in patients with platinum-resistant nasopharyngeal carcinoma.

Pathologic complete response rates with the atezolizumab combination were higher for patients with PD-L1–negative disease in the phase 2 ATHENE trial.

AUTO4 CAR T cells plus fludarabine and cyclophosphamide was well tolerated in patients with relapsed or refractory peripheral T cell lymphoma.

Daratumumab plus lenalidomide/dexamethasone for multiple myeloma showed improved 5-year health-related quality of life vs lenalidomide/dexamethasone alone.